|ALEKSANDRA KUCHARCZYK, KARINA JAHNZ-RÓŻYK, MARZENA JUSTYNA MIERZEJEWSKA, TOMASZ TARGOWSKI|
Introduction. The efficacy of injective immunotherapy in the treatment of IgE-dependent allergic diseases is no longer a matter of debate, but concerns about its safety and compliance problems due to a great number of visits required in the build-up phase are limiting factor for its widespread usage.
Aim of the study. The aim of the study was to investigate the safety of accelerated build-up schedule of conventional immunotherapy with Phostal in adults with seasonal rhinoconjunctivitis with or without asthma, allergic to grasses.
Material and methods. Assess, in the open, prospective study, the safety of accelerated (8 week) build-up schedule of immunotherapy in 24 grass pollen-sensitive patients with rhinitis or conjunctivitis, with or without the accompanying asthma.
Results. All of the patients were finally enlisted in the study. Significant adverse events were not observed.
Conclusion. Accelerated (8 week) schedule used instead of the standard (13 week) build-up schedule of immunotherapy did not increase the frequency of adverse events. Implementing new, safe and short schedules could lead to a better compliance and to a broader use of injective immunotherapy.
keywords: przyspieszony schemat odczulania, alergiczny nieżyt nosa, astma, accelerated immunotherapy, cluster schedule, allergic rhinitis, asthma
pages: from 155 to 159
|estimated time of download (144 kB)|